Brand Names:
Cipro


Drug Type: Antibiotic

Ciprofloxacin

Ciprofloxacin (Cipro) is a broad-spectrum fluoroquinolone antibiotic that is used to treat a variety of bacterial infections in humans. Baytril is the veterinary-labeled form of this same drug. Since this drug is a fluoroquinolone-class antibiotic, it is not approved for use in poultry that are not kept as pets.

Ciprofloxacin has good activity against most gram-negative bacteria, including Enterobacer, E.coli, Klebsiella, Pasteurella, Proteus, Salmonella, and sometimes Pseudomonas. It also has good activity against some gram-positive bacteria (Staphylococcus).

Caution: Should not be used in growing birds due to risk of damage to cartilage.

Storage
Oral: store tablets at room temperature, and store capsules and suspension diluent below 25° C (77° F), but do not freeze. Discard unused suspension after 14 days. Protect from light.

Injection: store flexible containers between 5° C and 25° C (41° F and 77° F) and IV infusion vials between 5° C and 30° C (41° F and 86° F). Avoid temperatures over 40° C (104° F) and protect from light. When injection is diluted for injection, it is stable for 2 weeks at either room temperature below 30° C (86° F) or when refrigerated between 2° C and 8° C (36° F and 46° F). Do not freeze.
  • 15-40 mg/kg PO, SC, IM, IV q12h
Available as a tablet (250, 500 or 750 mg) for oral administration, as an injectable solution (200 or 400 mg/ml) for slow IV administration, or as an ophthalmic solution (3 mg/mL).
  • May cause CNS problems and irritability.
  • Acetylsalicylic acid (Asprin): Acetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.
  • Calcium products: Calcium Acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Calcium Acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Carprofen: Carprofen may increase the neuroexcitatory activities of Ciprofloxacin.
  • Corticosterone: The risk or severity of adverse effects can be increased when Corticosterone is combined with Ciprofloxacin.
  • Curcumin: Curcumin may increase the neuroexcitatory activities of Ciprofloxacin.
  • Dexamethasone:The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ciprofloxacin.
  • Diclofenac:Diclofenac may increase the neuroexcitatory activities of Ciprofloxacin.
  • Digitoxin: Digitoxin may decrease the cardiotoxic activities of Ciprofloxacin.
  • Digoxin: Digoxin may decrease the cardiotoxic activities of Ciprofloxacin.
  • Enalapril: The risk or severity of ventricular arrhythmias can be increased when Enalapril is combined with Ciprofloxacin.
  • Erythromycin: Erythromycin may increase the QTc-prolonging activities of Ciprofloxacin.
  • Etodolac: Etodolac may increase the neuroexcitatory activities of Ciprofloxacin.
  • Evening primrose oil:Evening primrose oil may increase the neuroexcitatory activities of Ciprofloxacin.
  • Fluconazole:Fluconazole may increase the QTc-prolonging activities of Ciprofloxacin.
  • Flunixin: Flunixin may increase the neuroexcitatory activities of Ciprofloxacin.
  • Hydrocortisone: The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ciprofloxacin.
  • Iron: The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron.
  • Isoflurane:Isoflurane may increase the QTc-prolonging activities of Ciprofloxacin.
  • Itraconazole: Itraconazole may increase the QTc-prolonging activities of Ciprofloxacin.
  • Ketoconazole: Ketoconazole may increase the QTc-prolonging activities of Ciprofloxacin.
  • Ketoprofen: Ketoprofen may increase the neuroexcitatory activities of Ciprofloxacin.
  • Leuprolide: Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin.
  • Magnesium sulfate: The serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium sulfate.
  • Meloxicam: Meloxicam may increase the neuroexcitatory activities of Ciprofloxacin.
  • Methylprednisolone: The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ciprofloxacin.
  • Oxytocin: Oxytocin may increase the QTc-prolonging activities of Ciprofloxacin.
  • Pergolide: The risk or severity of adverse effects can be increased when Pergolide is combined with Ciprofloxacin.
  • Phenylbutazone: Phenylbutazone may increase the neuroexcitatory activities of Ciprofloxacin.
  • Prednisolone:The risk or severity of adverse effects can be increased when Prednisolone is combined with Ciprofloxacin.
  • Prednisone: The risk or severity of adverse effects can be increased when Prednisone is combined with ciprofloxacin.
  • Resveratrol:Resveratrol may increase the neuroexcitatory activities of Ciprofloxacin.
  • Sodium bicarbonate:Sodium bicarbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Sulfadiazine:Ciprofloxacin may increase the hypoglycemic activities of Sulfadiazine
  • Sulfamethoxazole:Sulfamethoxazole may increase the QTc-prolonging activities of Ciprofloxacin.
  • Tamoxifen:Tamoxifen may increase the QTc-prolonging activities of Ciprofloxacin.
  • Trimethoprim:Trimethoprim may increase the QTc-prolonging activities of Ciprofloxacin.
  • Voriconazole: Voriconazole may increase the QTc-prolonging activities of Ciprofloxacin.
  • Xanthinol:The serum concentration of Xanthinol can be increased when it is combined with Ciprofloxacin.

Popular Health Tools

Switch Animal